

# Francois Maignen

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7644038/publications.pdf>

Version: 2024-02-01

13  
papers

243  
citations

1162889

8  
h-index

1125617

13  
g-index

13  
all docs

13  
docs citations

13  
times ranked

308  
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparing access to orphan medicinal products in Europe. Orphanet Journal of Rare Diseases, 2019, 14, 95.	1.2	57
2	Late translational research: putting forward a new model for developing new anti-cancer treatments that addresses the needs of patients and society. Molecular Oncology, 2019, 13, 558-566.	2.1	13
3	Outcomes of early health technology assessment dialogues in medicinal product development. Nature Reviews Drug Discovery, 2017, 16, 79-79.	21.5	2
4	Integrating health technology assessment requirements in the clinical development of medicines: the experience from NICE scientific advice. European Journal of Clinical Pharmacology, 2017, 73, 297-305.	0.8	8
5	Does serious consequential masking exist? An update. Pharmacoepidemiology and Drug Safety, 2017, 26, 727-729.	0.9	2
6	OP138 Access To Orphan Drugs In The United Kingdom And Other European Countries. International Journal of Technology Assessment in Health Care, 2017, 33, 64-65.	0.2	4
7	A mathematical framework to quantify the masking effect associated with the confidence intervals of measures of disproportionality. Therapeutic Advances in Drug Safety, 2017, 8, 231-244.	1.0	11
8	Assessing the extent and impact of the masking effect of disproportionality analyses on two spontaneous reporting systems databases. Pharmacoepidemiology and Drug Safety, 2014, 23, 195-207.	0.9	37
9	A conceptual approach to the masking effect of measures of disproportionality. Pharmacoepidemiology and Drug Safety, 2014, 23, 208-217.	0.9	17
10	A Case of Therapy-Related Myeloid Neoplasm in a Patient with Crohn's Disease Treated with Azathioprine. Acta Haematologica, 2012, 128, 1-6.	0.7	8
11	Modelling the Time to Onset of Adverse Reactions with Parametric Survival Distributions. Drug Safety, 2010, 33, 417-434.	1.4	10
12	Validation of Statistical Signal Detection Procedures in EudraVigilance Post-Authorization Data. Drug Safety, 2010, 33, 475-487.	1.4	73
13	Transgenic Expression of Human Platelet Fcγ <sub>3</sub> RIIA (CD32A) in Mice Does Not Affect the Thrombocytopenia Associated with WASp Deficiency.. Blood, 2006, 108, 1106-1106.	0.6	1